These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 18931565)

  • 1. [Cardiac toxicity and edema].
    Takeuchi S; Sakai H
    Gan To Kagaku Ryoho; 2008 Oct; 35(10):1654-8. PubMed ID: 18931565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study.
    Bengala C; Zamagni C; Pedrazzoli P; Matteucci P; Ballestrero A; Da Prada G; Martino M; Rosti G; Danova M; Bregni M; Jovic G; Guarneri V; Maur M; Conte PF;
    Br J Cancer; 2006 Apr; 94(7):1016-20. PubMed ID: 16570045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trastuzumab-associated cardiotoxicity.
    Keefe DL
    Cancer; 2002 Oct; 95(7):1592-600. PubMed ID: 12237930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond chemotherapy--demystifying the new 'targeted' cancer treatments.
    Dear R; Wilcken N; Shannon J
    Aust Fam Physician; 2008; 37(1-2):45-9. PubMed ID: 18239753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cardiac dysfunction induced by trastuzumab].
    Campone M; Bourbouloux E; Fumoleau P
    Bull Cancer; 2004 Nov; 91 Suppl 3():166-73. PubMed ID: 15899624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac toxicity from systemic cancer therapy: a comprehensive review.
    Curigliano G; Mayer EL; Burstein HJ; Winer EP; Goldhirsch A
    Prog Cardiovasc Dis; 2010; 53(2):94-104. PubMed ID: 20728696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversing resistance to targeted therapy.
    Vidal L; Attard G; Kaye S; De Bono J
    J Chemother; 2004 Nov; 16 Suppl 4():7-12. PubMed ID: 15688600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical cardiac tolerability of trastuzumab.
    Perez EA; Rodeheffer R
    J Clin Oncol; 2004 Jan; 22(2):322-9. PubMed ID: 14722042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trastuzumab beyond progression: is the risk of cardiac toxicity really not increased?
    Morabito A; Piccirillo MC; De Maio E; Di Maio M; Perrone F
    J Clin Oncol; 2009 Sep; 27(27):e123; author reply e124-5. PubMed ID: 19687322
    [No Abstract]   [Full Text] [Related]  

  • 10. Imatinib mesylate (Gleevec) induced unilateral optic disc edema.
    DeLuca C; Shenouda-Awad N; Haskes C; Wrzesinski S
    Optom Vis Sci; 2012 Oct; 89(10):e16-22. PubMed ID: 22960614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes.
    Gianni L; Salvatorelli E; Minotti G
    Cardiovasc Toxicol; 2007; 7(2):67-71. PubMed ID: 17652806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer.
    Suter TM; Cook-Bruns N; Barton C
    Breast; 2004 Jun; 13(3):173-83. PubMed ID: 15177418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Indications for Herceptin in breast cancer treatment].
    Beuzeboc P
    Gynecol Obstet Fertil; 2004 Feb; 32(2):164-72. PubMed ID: 15123142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trastuzumab versus lapatinib: the cardiac side of the story.
    Azim H; Azim HA; Escudier B
    Cancer Treat Rev; 2009 Nov; 35(7):633-8. PubMed ID: 19640652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Appearance of skin and nail toxicity in patients with breast cancer who underwent trastuzumab-containing chemotherapy].
    Adachi S; Yoshimura T; Matsuoka T; Okada K; Yasuda T; Kamei K
    Gan To Kagaku Ryoho; 2011 Sep; 38(9):1453-6. PubMed ID: 21918340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intramuscular edema as a complication of treatment with imatinib.
    Shimazaki C; Ochiai N; Uchida R; Fuchida SI; Okano A; Ashihara E; Inaba T; Fujita N; Nakagawa M
    Leukemia; 2003 Apr; 17(4):804-5. PubMed ID: 12682642
    [No Abstract]   [Full Text] [Related]  

  • 17. Ocular side effects in chronic myeloid leukemia patients treated with imatinib.
    Breccia M; Gentilini F; Cannella L; Latagliata R; Carmosino I; Frustaci A; Alimena G
    Leuk Res; 2008 Jul; 32(7):1022-5. PubMed ID: 18061664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tomorrow's targeted therapies in breast cancer patients: what is the risk for increased radiation-induced cardiac toxicity?
    Magné N; Chargari C; MacDermed D; Conforti R; Védrine L; Spano JP; Khayat D
    Crit Rev Oncol Hematol; 2010 Dec; 76(3):186-95. PubMed ID: 20138541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cardiologic follow up of an oncologic patient].
    Zaugg Longchamp D; Zaman K; Aebischer N
    Rev Med Suisse; 2010 Jun; 6(251):1133-4, 1136-9. PubMed ID: 20572357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiotoxicity associated with trastuzumab treatment of HER2+ breast cancer.
    Fiúza M
    Adv Ther; 2009 Jul; 26 Suppl 1():S9-17. PubMed ID: 19669637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.